Authors' disclosures of potential conflicts of interest are found at the end of this article. T he management of chronic lymphocytic leukemia (CLL), a malignant disorder of the lymphoid lineage (primarily B cells), has changed considerably in recent years. The development of agents targeting CD20, a trans-membrane calcium channel protein expressed on B cells, was a significant milestone in the ...

Murine monoclonal antibody 2B8 specifically recognizes the CD20 phosphoprotein expressed on the surface of normal B lymphocytes and B-cell lymphomas. The light- and heavy-chain variable regions of 2B8 were cloned, after amplification by the polymerase chain reaction, into a cDNA expression vector that contained human IgG1 heavy chain and human kappa-light chain constant regions. High-level expr...

NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...

Anti-CD20 monoclonal antibodies (mAbs) represent an effective treatment for a number of B cell malignancies and autoimmune disorders. Glycoengineering of anti-CD20mAb may contribute to increased anti-tumor efficacy through enhanced antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADP) as reported by in vitro studies. However, where and how glycoengineered Ab may potentiate ther...

PURPOSE We aimed to develop and translate a CD20-antigen-targeted radiopharmaceutical, Technetium-99 m-labeled (99mTc) rituximab, for sentinel lymph node (SLN) detection. METHODS 99mTc-rituximab was synthesized and tested for stability in human serum. The binding affinity to CD20 was evaluated in Raji cells by flow cytometric analysis. Biodistribution and sentinel node mapping were carried ou...

Despite the rapid and widespread integration of chimeric CD20 monoclonal antibody (mAb), rituximab, into the management of non-Hodgkin lymphoma, its efficacy remains variable and often modest when used as a single agent. To develop more potent reagents, human immunoglobulin transgenic mice were used to generate a panel of immunoglobulin G1kappa (IgG1kappa) CD20 mAbs. All reagents bound strongly...

word count: 194 Scientific Heading: Neoplasia Copyright (c) 2003 American Society of Hematology Blood First Edition Paper, prepublished online October 9, 2003; DOI 10.1182/blood-2003-06-2031 For personal use only. on October 3, 2017. by guest www.bloodjournal.org From

Abstract Natural killer (NK) cells are innate lymphocytes capable of mediating immune responses without prior sensitization. NK express Fc-gamma receptors (FcγR) that engage the Fc region IgG. Studies investigating role FcγR on mouse have been limited due to lack specific reagents. In this study, we characterize expression and biological consequences activating through their FcγR. We demonstrat...

To the Editor: Pemphigus foliaceus (PF) is a chronic autoimmune blistering disease caused by pathogenic serum autoantibodies against desmoglein 1. Initial treatments for PF include systemic corticosteroids, immunosuppressants, and dapsone.1 Rituximab, chimeric monoclonal antibody specific to CD20 molecule on B cells, was shown be effective severe refractory cases of pemphigus in meta-analysis.2...

NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...